Olanzapine intramuscular shows better efficacy than zuclopenthixol acetate intramuscular in reducing the need for restraint, but not in comparison to haloperidol intramuscular.
Journal
International clinical psychopharmacology
ISSN: 1473-5857
Titre abrégé: Int Clin Psychopharmacol
Pays: England
ID NLM: 8609061
Informations de publication
Date de publication:
01 01 2022
01 01 2022
Historique:
pubmed:
27
11
2021
medline:
11
3
2022
entrez:
26
11
2021
Statut:
ppublish
Résumé
Many psychotic patients are treated with antipsychotic medications during acute agitation and aggressive behavior episodes in an attempt to achieve a rapid calming effect. Those medications include olanzapine, zuclopenthixol acetate, and haloperidol intramuscular administration. This study compared the effectiveness of these injections in reducing the need for restraint during agitated-psychotic episodes that include aggression. Sociodemographical and clinical data were retrieved from the electronic medical records of 179 patients who needed rapid calming while hospitalized in a mental health center with acute psychosis. The treatments administered were olanzapine intramuscular, zuclopenthixol acetate intramuscular, and haloperidol intramuscular. The assessed outcomes were rate of restraint and violent behavior. Olanzapine was found significantly more effective in reducing the need for restraint compared to zuclopenthixol acetate. No significant differences were found between haloperidol and the other two with regard to restraint. Neither were other significant differences found between the groups with regard to violent or self-harming behaviors. No significant differences were found in the rate of violent behavior and antipsychotic dosage at discharge. In conclusion, in inpatients with acute agitated psychosis, olanzapine intramuscular shows better efficacy in reducing the need for restraint, at least as compared to zuclopenthixol acetate intramuscular.
Identifiants
pubmed: 34825897
doi: 10.1097/YIC.0000000000000381
pii: 00004850-202201000-00002
doi:
Substances chimiques
Antipsychotic Agents
0
clopenthixol acetate ester
0A4EBG0F53
Benzodiazepines
12794-10-4
Clopenthixol
982-24-1
Haloperidol
J6292F8L3D
Olanzapine
N7U69T4SZR
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-13Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Belgamwar RB, Fenton MOlanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnesses. Cochrane Database Syst Rev 2005). 2005:CD003729.
Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Madrigal M, Hernández GFrequency of extrapyramidal adverse reactions in schizophrenic outpatients treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Clin Drug Investig 2002). 22:609–622.
Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, et al. (A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002). 59:441–448.
Castle DJ, Udristoiu T, Kim CY, Sarosi A, Pidrman V, Omar AN, et al. (Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: comparison of real-life effectiveness in the treatment of agitation. World J Biol Psychiatry 2009). 10:43–53.
Cookson JRapid tranquillisation: the science and advice. BJPsych Adv 2018). 24:346–358.
de Almeida CG, Del Grossi Moura M, Barberato-Filho S, de Sá Del Fiol F, Motta RHL, de Cássia Bergamaschi CRapid tranquilization for psychiatric patients with psychomotor agitation: what is known about it? Psychiatr Q 2017). 88:885–895.
Fernández-Costa D, Gómez-Salgado J, Fagundo-Rivera J, Martín-Pereira J, Prieto-Callejero B, García-Iglesias JJAlternatives to the use of mechanical restraints in the management of agitation or aggressions of psychiatric patients: a scoping review. J Clin Med 2020). 9:E2791.
Foster S, Kessel J, Berman ME, Simpson GMEfficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 1997). 12:175–179.
Innes J, Sethi FCurrent rapid tranquillisation documents in the UK: a review of the drugs recommended, their routes of administration and clinical parameters influencing their use. J Psychiatr Intensive Care 2012). 9:110–118.
Jayakody K, Gibson RC, Kumar A, Gunadasa SZuclopenthixol acetate for acute schizophrenia and similar serious mental illnesses. Cochrane Database Syst Rev 2012). 2012:CD000525.
Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki JOlanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. J Clin Psychopharmacol 2008). 28:601–607.
Leucht S, Samara M, Heres S, Davis JMDose equivalents for antipsychotic drugs: the DDD method. Schizophr Bull 2016). 42(suppl 1):S90–S94.
Meehan K, Zhang F, David S, Tohen M, Janicak P, Small J, et al. (A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001). 21:389–397.
Schleifer JJManagement of acute agitation in psychosis: an evidence-based approach in the USA. Adv Psychiatr Treatment 2018). 17:91–100.
Simpson JR, Thompson CR, Beckson M. (Impact of orally disintegrating olanzapine on use of intramuscular antipsychotics, seclusion, and restraint in an acute inpatient psychiatric setting. J Clin Psychopharmacol. 2006). 26:333–335.
Stewart D, Van der Merwe M, Bowers L, Simpson A, Jones JA review of interventions to reduce mechanical restraint and seclusion among adult psychiatric inpatients. Issues Ment Health Nurs 2010). 31:413–424.
Sullivan D, Wallis M, Lloyd CEffects of patient-focused care on seclusion in a psychiatric intensive care unit. Int J Therapy Rehab 2004). 11:503–508.
Suzuki H, Gen K, Takahashi YA naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia. Hum Psychopharmacol 2014). 29:83–88.
Wright P, Birkett M, David SR, Meehan K, Ferchland I, Alaka KJ, et al. (Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001). 158:1149–1151.
Zareifopoulos N, Panayiotakopoulos GTreatment options for acute agitation in psychiatric patients: theoretical and empirical evidence. Cureus 2019). 11:e6152.